The high expression level of SPARC leads to the low survival rate of PAAD patients, so that during 70 months, the mortality rate was proximately 100%, and the five-year survival rate was 10% which is not very much based on the differences in the expression level in various stages. The gene discussed is SPARC; the disease is pancreatic adenocarcinoma.